The latest update is out from Corbus Pharmaceuticals ( (CRBP) ).
Corbus Pharmaceuticals reported its first quarter 2025 financial results, highlighting a net loss of $17 million, primarily due to increased clinical development expenses. The company is advancing its pipeline with ongoing studies for CRB-701, CRB-913, and CRB-601, with significant data expected in the second half of 2025. The FDA granted Fast Track designation to CRB-701 for metastatic cervical cancer, indicating potential regulatory advancements.
Spark’s Take on CRBP Stock
According to Spark, TipRanks’ AI Analyst, CRBP is a Neutral.
Corbus Pharmaceuticals’ overall stock score is driven by severe financial challenges, including no recent revenue and high net losses, which significantly weigh down its score. However, technical indicators suggest some short-term positive momentum. The promising Phase 1 trial results provide a potential catalyst in the biotechnology field, offering some positive outlook despite the current financial difficulties.
To see Spark’s full report on CRBP stock, click here.
More about Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company based in Norwood, Massachusetts. It focuses on developing innovative treatments targeting well-understood biological pathways. The company’s portfolio includes CRB-701, an antibody drug conjugate for cancer, CRB-601, an anti-integrin monoclonal antibody for solid tumors, and CRB-913, a CB1 receptor inverse agonist for obesity.
Average Trading Volume: 225,530
Technical Sentiment Signal: Sell
Current Market Cap: $95.29M
For detailed information about CRBP stock, go to TipRanks’ Stock Analysis page.